FDA approves Latitude patient management system upgrade

Jeff Byers | | Health Exec | Digital Transformation
The FDA has approved Boston Scientific’s Latitude 6.0, a software upgrade to the company's Latitude patient management system.

The system enables physicians to remotely monitor patients with implantable cardiac devices and provides functionality, including the ability to view a history of a patient's remote follow-up data, according to the Natick, Mass.-based health IT company.

According to Boston Scientific, the system can detect changes in a patient's heart health status between scheduled follow-up visits and send relevant data and alerts directly to physicians.

The Latitude patient management system will be demonstrated at Boston Scientific's booth (#1017) during the 31st Annual Scientific Sessions of the Heart Rhythm Society, May 13 - 15 in Denver.

Jeff Byers

Related Content

From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI
Healthcare-specific AI: How to multiply successes and head off accidents

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.